Original Research Paper

Hepatic Injury In Covid 19 Patients Treated With Remdesivir And Its Interaction With Hcq

Abstract :

IntroductionNovel severe acute respiratory syndrome corona virus 2 (SARS COV 2) can lead to direct liver injury. Therefore monitoring of liver function test is important. However, the hepatic safety of Remdesivir is not clear due to the limited experience. Relationship between drug-drug interaction of Remdesivir and HCQ is also not clear.ObjectivesTo describe the incidence and characteristics of Remdesivir induced hepatic injury among COVID 19 patients and to assess its interaction with HCQ at Sree Mookambika Institute of medical sciences, Kulasekharam, Kanyakumari.MethodologyMedical Record review of 51 patients who fulfilled eligibility criteria and treated with Remdesivir at Sree Mookambika Institute of Medical Sciences, Kanyakumari. Results Among the patient treated with Remdesivir and HCQ, 25 patients had elevated liver enzymes above 5 times of upper normal limit. Among the Patient treated with Remdesivir alone, only 1 patient had elevated liver enzymes above 5 times of upper normal limit. The p value is 0.012 and it is significant.Conclusion: Elevated liver enzymes is more common in patients treated with both Remdesivir and HCQ than patients treated with Remdesivir alone. This clearly shows that the influence of p-gp inhibitors on hepatotoxicity of Remdesivir. Therefore, Physicians should be cautious while using p-gp inhibitors for patient who is on treatment with Remdesivir.

Cite This Article:

References :